ForPatients
by Roche

Alzheimer's Disease (AD)

Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease

Trial Status	Trial Runs In	Trial Identifier
Not yet recruiting		NCT07781657 2026-526158-14-00 BP46554

The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

Official Title:

A Phase II, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of RO7568282 in Participants With Early Symptomatic Alzheimer's Disease

Trial Summary:

This study aims to compare the effects of RO7568282 versus a placebo in people in the early stages of Alzheimer's disease (AD).

Hoffmann-La Roche	Phase 2
Sponsor	Phase

NCT07781657 2026-526158-14-00 BP46554
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	#50 Years & # 90 Years	No

Inclusion Criteria:

- Evidence of AD pathological process, as confirmed by either amyloid positron emission tomography (PET) scan or cerebrospinal fluid (CSF)
- Mild cognitive impairment (MCI) or mild dementia due to AD
- Able to swallow whole capsules
- Body mass index (BMI) within the range of 18-34 kilograms per square metre (kg/m^2) (at screening)
- Availability of an appropriate study partner

Exclusion Criteria:

- Any evidence of a condition other than AD that may affect cognition
- Participants must not have unstable or clinically significant cardiovascular disease within the last year, chronic uncontrolled hypertension, or clinically significant electrocardiogram (ECG) abnormalities
- History or presence of clinically significant cerebrovascular disease
- Clinically significant cerebral abnormalities on magnetic resonance imaging (MRI)

Note: Other protocol-defined inclusion/exclusion criteria may apply.